Prevent Cardiac Surgery Associated AKI Trial
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-70
SponsorGeorge Washington University
About this trial
Prevent CSA-AKI (Cardiac Surgery Associated Acute Kidney Injury) trial is a double blinded randomized controlled trial, 242 patients undergoing elective cardiopulmonary bypass surgery (CPB)will either receive a placebo or daily 1200 mg of Co enzyme Q10 (CoQ10) and 1000 mg of Glutathione (GSH), the first dose will be given the day before surgery and continues while admitted up to 1 week. Blood and urine samples will be collected. Adverse events related to the study drugs will be collected.
Eligibility criteria
Qualifiers
Adult 18-70 years of age
Undergoing elective CPB (Cardiopulmonary Bypass) surgery
Baseline GFR (Glomerular Filtration Rate) ≥45 ml/min
Disqualifiers
GFR (Glomerular Filtration Rate) <45 ml/min
Solitary kidney
Status post-kidney transplant
Pregnant women
Trial design
Treatments tested in this trial
- CoQ10 1200 mg orally with Glutathione 1000 mg orally
- Group B: Placebo CoQ10 orally and Placebo Glutathione orally
Treatment groups
242 Participants
are divided into 2 treatment groupsLocations
1George Washington University Hospital20037, Washington D.C.District of Columbia, United States
Sponsors and collaborators
George Washington University
Lead sponsor
Source ClinicalTrials.gov